Health

  • May 21, 2026

    Clark Hill Exits NJ Health Noncompete Dispute After DQ Bid

    A New Jersey federal judge has signed off on a request from Clark Hill PLC to withdraw as counsel for a nursing home operator amid an adversary's disqualification motion in a noncompete dispute with a medical consulting company.

  • May 21, 2026

    Medical Practice Calls $49M Missed Cancer Verdict 'Unjust'

    The Westchester Medical Group PC has asked a Connecticut state judge to find most of a $49 million jury verdict "excessive, unjust, and entirely disproportionate" to claims its staff repeatedly failed to diagnose cancer despite multiple warning signs, calling the award punitive and not supported by the evidence.

  • May 21, 2026

    Meta, Others Settle Bellwether School Case Set For June Trial

    Meta Platforms Inc., Snap Inc., TikTok Inc. and YouTube have each agreed to settle a bellwether school district's claims in social media addiction multidistrict litigation that were set for a six-week California federal jury trial beginning June 12, according to the Kentucky school district's counsel.

  • May 21, 2026

    Barnes & Thornburg Adds Boston Litigator From Nutter

    Barnes & Thornburg LLP has hired a longtime Nutter McClennen & Fish LLP partner in Boston who will focus on commercial litigation and product liability matters for healthcare, medical devices and manufacturing clients, the firm announced Thursday.

  • May 21, 2026

    AmeriHealth Unit, PBM Sued Over Prescription Claim Fees

    Two Philadelphia pharmacies have filed a proposed class action against AmeriHealth Caritas Health Plan and its in-house pharmacy benefits manager, PerformRx LLC, claiming the companies violate Pennsylvania law by not disclosing "transmission fees" at the time a claim is run through the pharmacies' computers, according to a complaint removed to federal court.

  • May 21, 2026

    Ga. Panel Says Trial Court Wrongly Denied New Med Mal Trial

    A Georgia appeals panel has sent a man's malpractice suit back to trial court, finding the lower court judge wrongly denied his motion for a new trial when he determined that the jury was required to decide whether gross negligence standards applied to the case.

  • May 20, 2026

    DOJ, Drugmakers Spar After Justices Snub 6 Negotiation Suits

    The U.S. Department of Justice is trying to have it both ways in drug pricing litigation, telling the U.S. Supreme Court not to intervene before additional circuits decide pending challenges and then using this week's nonintervention as ammunition against those challenges, drugmakers are arguing at appeals courts.

  • May 20, 2026

    Anthem Affiliates Can't Duck Suit Over Colo. Claims

    A mental health and substance use disorder treatment provider told a Colorado judge that affiliates of Anthem Blue Cross and Blue Shield can't get an early escape from its lawsuit accusing the affiliates of underpaying claims from some of its patients, according to a brief filed in federal court.

  • May 20, 2026

    1st Circ. Allows Transfer Of RI Youth Care Info To Texas Court

    The First Circuit declined to halt a Texas federal court's order requiring a Rhode Island hospital to hand over records detailing its provision of gender-affirming care to minors, finding a Rhode Island agency failed to demonstrate that doing so would cause children in the state irreparable harm.

  • May 20, 2026

    Refusing Sandoz Parent Dismissal 'Clear Error,' Court Told

    Sandoz's Swiss parent company wants a Pennsylvania federal judge to rethink her decision forcing it to face generic drug price-fixing claims from major employers like General Motors, arguing the court "conflates" Novartis AG with Sandoz AG, which was spun off in 2023.

  • May 20, 2026

    Eli Lilly Loses Bid To Limit Ex-FDA Chief's Take In GLP-1 MDL

    A Pennsylvania federal judge said Eli Lilly & Co. and plaintiffs in multidistrict litigation accusing it of downplaying side effects of weight loss drugs were talking past each other in a dispute over expert testimony, denying Eli Lilly's bid to limit the opinions of the plaintiffs' expert to those disclosed in his report.

  • May 20, 2026

    Antivax Health Workers Fight Uphill At 9th Circ. Over Firings

    Two Ninth Circuit panelists cast doubt Wednesday on an attempt by a group of former University of Washington employees to revive claims that they were wrongfully fired after they refused COVID-19 vaccination on religious grounds, with one judge remarking that unvaccinated workers "make the risk worse" in a healthcare setting.

  • May 20, 2026

    NY Hospital Strikes Deal In Suit Over Retirement Plan Lineup

    A Long Island hospital agreed to settle a proposed class action alleging it cost workers millions of dollars in savings by loading its employee retirement plan with costly and underperforming investment options, according to a filing in New York federal court Wednesday.

  • May 20, 2026

    Eli Lilly Paying Up To $202M In Genetic Medicine Deal

    Eli Lilly and Co. has agreed to acquire privately held Engage Biologics Inc., which is developing a delivery technology for genetic medicines, in a deal worth up to $202 million, Cooley LLP-advised Engage announced Wednesday.

  • May 20, 2026

    Lloyd's Can't Undo Remand Order In Hurricane Damage Fight

    A Virgin Islands federal court on Wednesday refused to reconsider its decision to remand an ophthalmology clinic's suit over the handling of its Hurricane Maria property damage claim back to territorial court, saying there was no "clear error" or "manifest injustice" to correct.

  • May 20, 2026

    Pa. AG Aims To Revive Ban On Medicaid-Paid Abortions

    Pennsylvania Attorney General Dave Sunday plans to fight an appellate panel's ruling that Medicaid-funded abortions are a fundamental right to reproductive autonomy in the state.

  • May 20, 2026

    FTC 'Close' To Final PBM Insulin Price Deal With OptumRx

    Federal Trade Commission staffers have signaled that they're near a settlement with UnitedHealth Group Inc.'s OptumRx that would close out the agency's in-house case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes.

  • May 20, 2026

    DOJ's Embrace Of Data Sets Off Compliance 'Arms Race'

    The U.S. Department of Justice's increased reliance on advanced data analytics and data-mining whistleblowers to detect fraud is shrinking the amount of time that companies have to find and report potential wrongdoing to the government in order to receive leniency for voluntary self-disclosure, experts say.

  • May 20, 2026

    Modivcare To Have Evidence Hearing On Firm's Contempt Bid

    A Texas bankruptcy judge said Wednesday he would call an evidentiary hearing on White & Case's motion to hold Modivcare in contempt connected to a Chapter 11 fee dispute, after the firm accused the reorganized medical transportation group of taking $3.5 million of what should have been escrowed funds out of an account.

  • May 19, 2026

    Quinn Emanuel Owes More Sanctions In Guardant Fight

    Quinn Emanuel and its team representing medical testing company Natera will shoulder further sanctions on top of the $3 million already imposed over the firm's misrepresentations concerning an expert witness in Guardant Health's false advertising case, a California federal judge ruled Tuesday.

  • May 19, 2026

    Calif. Urges 9th Circ. To Revive Pay-For-Delay Restrictions

    California urged a Ninth Circuit panel Tuesday to find a Golden State law that bans drugmakers from cutting deals out of state that pay to delay generics competition doesn't violate the U.S. Constitution, arguing that ruling otherwise could jeopardize many longstanding state laws that regulate out-of-state conduct.

  • May 19, 2026

    McDermott-Led Albaron Wraps $185M Healthcare Fund

    Albaron Partners, advised by McDermott Will & Schulte, on Tuesday revealed it has closed its flagship fund after securing $185 million in commitments, which will be used to invest in healthcare companies.

  • May 19, 2026

    Cigna Can't Knock Out 401(k) Forfeiture, Fund Suit

    Cigna can't escape a proposed class action alleging that underperforming investment offerings and misallocated forfeitures in its employee 401(k) plan cost workers millions, after a Pennsylvania federal judge ruled Tuesday that alleged violations of federal benefits law were sufficiently backed up to reach discovery.

  • May 19, 2026

    Squires Ends Samsung-Requested IPR Over Related PGR

    The Patent Trial and Appeal Board will no longer conduct an inter partes review into the validity of an Omni MedSci wearable device patent, now that there will be a separate post-grant review.

  • May 19, 2026

    Fed. Circ. Rehearing Sought In $18M Penile Implant Dispute

    The Federal Circuit has been asked to have another look at a decision that largely reversed a California federal jury verdict that awarded $18.3 million to International Medical Devices Inc. in a trade secret case related to penile implants.

Expert Analysis

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • Employment Immigration Trends And Challenges For 2026

    Author Photo

    U.S. companies competing for global talent should brace for a turbulent 2026, with greater compliance burdens, higher costs and the probability of workforce disruptions at every stage of the immigration process, from visa petitions to work authorization renewals, say attorneys at Duane Morris.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • Health, Legal Employers Face Unique Online Speech Hurdles

    Author Photo

    Employers in the legal and healthcare industries must consider distinctive ethical obligations and professional requirements when disciplining employees for social media posts, while anticipating an area of the law in flux as courts seek to balance speech rights and the workplace function, say attorneys at FordHarrison.

  • Reviewing 2025's Most Pertinent Wiretap Developments

    Author Photo

    2025 was a remarkable year in the world of web tracking wiretapping litigation, not only for the increased caseload but also because of numerous developing theories of liability, with disputes expected to continue unabated in 2026, say attorneys at Squire Patton.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • 2025 State AI Laws Expand Liability, Raise Insurance Risks

    Author Photo

    As 2025 nears its end, claims professionals should be aware of trends in state legislation addressing artificial intelligence use, as insurance claims based on some of these liability-expanding statutes are a certainty, say attorneys at Wiley.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

  • Opinion

    A Uniform Federal Rule Would Curb Gen AI Missteps In Court

    Author Photo

    To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.